Skip to main content
Premium Trial:

Request an Annual Quote

Sirna to Close $18M Private Placement

NEW YORK, April 30 (GenomeWeb New) - Sirna Therapeutics announced today that it has made agreements with institutional investors for the private placement of $18 million, or $3.25 per share, worth of common stock.

 

The private placement is expected to close during the first week of May.

 

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.